BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JCR Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies JCR Pharmaceuticals's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT01761968-3348@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Givinostat: Phase 2 readout est. (NCT01761968)
DESCRIPTION:Givinostat\, phase 2.\nStudy: Long-term Study Evaluating the Ef
 fect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/givinostat#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT01761968
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933057-3348@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Givinostat: Phase 3 readout est. (NCT05933057)
DESCRIPTION:Givinostat\, phase 3\, Duchenne Muscular Dystrophy.\nStudy: Eff
 icacy\, Safety and Tolerability of Givinostat in Non-ambulant Patients Wit
 h Duchenne Muscular Dystrophy\nEstimated primary completion: February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/givinostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05933057
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07568535-87@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Ryoncil (remestemcel-L): Phase 3 readout est. (NCT07568535)
DESCRIPTION:Ryoncil (remestemcel-L)\, phase 3\, Graft-versus-Host Disease.\
 nStudy: A Randomized\, Double-Blind\, Placebo-Controlled\, Multicenter Pha
 se III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV S
 teroid-Refractory Acute Graft-Versus-Host Disease\nEstimated primary compl
 etion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/remestemcel-l#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07568535
URL:https://assetmemo.bio/drug/remestemcel-l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769633-3348@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Givinostat: Phase 2 readout est. (NCT06769633)
DESCRIPTION:Givinostat\, phase 2\, Duchenne Muscular Dystrophy.\nStudy: Pha
 rmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 
 2 Years to Less Then 6 Years Old\nEstimated primary completion: December 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/givinostat#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06769633
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03373968-3348@assetmemo.bio
DTSTAMP:20261121T005719Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Givinostat: Phase 2/3 readout est. (NCT03373968)
DESCRIPTION:Givinostat\, phase 2/3\, Duchenne Muscular Dystrophy.\nStudy: G
 ivinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerabili
 ty Study\nEstimated primary completion: December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/givinostat#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03373968
URL:https://assetmemo.bio/drug/givinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
